Common genetic variants in the chromogranin a promoter are associated with renal injury in IGA nephropathy patients with malignant hypertension

Renal Failure

Volumn 32, Issue 1, 2010, Pages 41-46

  Yu, L ^a   Jiang, L ^a   Zhou, X J ^a   Zhu, L ^a   Zhang, H ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Chromogranin A; IgA nephropathy; Malignant hypertension; Polymorphism; Renal function

Indexed keywords

CHROMOGRANIN A;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 76449112212     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903377597     Document Type: Article

References (24)

1. Taupenot L, Harper KL, O'Connor DT. The chromograninsecretogranin family. N Engl J Med. 2003;348:1134-1149.
2. Winkler H, Fischer-Colbrie R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience. 1992;49:497-528.
3. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'Connor DT. Chromogranin A. Storage and release in hypertension. Hypertension. 1990;15:237-246.
4. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell. 2001;106:499-509.
5. Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catastatic (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem. 1999;274:2920-2928.
6. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100:1623-1633.
7. Chen Y, Rao F, Rodriguez-Flores JL, et al. Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int. 2008;74:115-125.
8. Salem RM, Cadman PE, Chen Y, et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol. 2008;19:600-614.
9. Beutler JJ, Koomans HA. Malignant hypertension: Still a challenge. Nephrol Dial Transplant. 1997;12:2019-2023.
10. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol. 1998;9:133-142.
11. Jiang L, Zhang JJ, Lv JC, et al. Malignant hypertension in IgA nephropathy was not associated with background pathological phenotypes of glomerular lesions. Nephrol Dial Transplant. 2008;23:3921-3927.
12. Zuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis. 2005;45: 463-472.
13. Guobing X, Lili J, Lihua Z, Tiean X. Application of an improved biuret method to the determination of total protein in urine and cerebrospinal fluid without concentration step by use of Hitachi 7170 auto-analyzer. J Clin Lab Anal. 2001;15:161-164.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
15. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
16. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association of traits with haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425-434.
17. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Human Heredity. 2003;55:56-65.
18. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296: 2225-2229.
19. Nyholt DR. A simple correction for multiple testing for single- nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765-769.
20. Chen Y, Tang Z, Yang G, et al. Malignant hypertension in patients with idiopathic IgA nephropathy. Kidney Blood Press Res. 2005;28:251-258.
21. Cheng XY, Zhao MH, Li XM, Liu YC. Clinical features and prognostic factors of chronic glomerulonephritis with malignant hypertension. Chin J Nephrol. 2004;20:79-82.
22. Zhou F, Liu Y, Zou W, Zhang Y, Wang H. Malignant hypertension presenting with renal damage: A clinical and pathological analyses. Chin J Intern Med. 2001; 40: 165-168.
23. Yu SH, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: Aetiology and outcome in 83 patients. Clin Exp Hypertens A. 1986;8:1211-1230.
24. Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol. 2008;28:1-7.